TONIGHT! Join in as Kyle Dennis, 27 year-old,
self-made millionaire, reveals his newest trading strategy.
self-made millionaire, reveals his newest trading strategy.
Days
Hours
Minutes
Seconds
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CELG | Celgene Corporation | -1.14% | 78.63 | 1.2% | $618.81m | |
| AMGN | Amgen Inc. | 0.16% | 178.24 | 1.2% | $557.24m | |
| GILD | Gilead Sciences, Inc. | -0.22% | 67.38 | 0.9% | $542.96m | |
| BIIB | Biogen Inc. | 0.63% | 286.21 | 1.2% | $478.24m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.30% | 293.74 | 2.6% | $304.78m | |
| VRTX | Vertex Pharmaceuticals Incorporated | 0.34% | 157.50 | 1.9% | $219.69m | |
| ALXN | Alexion Pharmaceuticals, Inc. | 0.51% | 117.74 | 2.0% | $210.05m | |
| ILMN | Illumina, Inc. | -1.70% | 266.22 | 3.5% | $198.41m | |
| A | Agilent Technologies, Inc. | -1.50% | 63.16 | 1.5% | $196.40m | |
| NKTR | Nektar Therapeutics | -0.77% | 79.96 | 6.0% | $184.19m | |
| INCY | Incyte Corporation | 2.64% | 68.43 | 2.5% | $149.75m | |
| BMRN | BioMarin Pharmaceutical Inc. | 4.77% | 92.49 | 4.4% | $135.47m | |
| SRPT | Sarepta Therapeutics, Inc. | 1.85% | 91.65 | 16.6% | $126.22m | |
| BLUE | Bluebird Bio, Inc. | 0.62% | 188.15 | 15.7% | $98.65m | |
| EXAS | Exact Sciences Corporation | -1.95% | 51.82 | 25.5% | $98.64m |
Company Profile
Idera Pharmaceuticals, Inc. is a clinical stage biotechnology company, which focuses on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. The company uses two distinct proprietary drug discovery technology platforms to design and develop drug candidates: Toll-like receptor targeting technology and third-generation antisense technology. The company was founded by Paul C. Zamecnik, Sudhir A. Agrawal, and James B. Wyngaarden on May 25, 1989 and is headquartered in Cambridge, MA.